Anti-Mouse H-2K^b (MHC Class I, Clone AF6-88.5) – Biotin

Mouse C57BL Splenocytes

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2, containing 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Clone AF6-88.5, Anti-Mouse H-2Kb, recognizes an epitope on mouse MHC class I H-2K haplotype b. AF6-88.5 does not cross-react with other H-2K haplotypes, including d, f, j, k, p, q, r, s, u, v.

H-2Kb antibody, clone A4C8.1-Do9, recognizes the major histocompatibility complex (MHC) class I H-2K haplotype b (H-2Kb). MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)^1,2. The α-chain consists of three domains (α1, α2, and α3)³. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens^4-6. β2M noncovalently associates with α3, which is essential for MHC stability. H-2Kb plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation⁷. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I to augment TCR signaling⁸. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance⁹. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity^10,11.

The AF6-88.5 antibody reacts with H-2Kb MHC class I alloantigen and is ubiquitously expressed on nucleated cells from mice of the H-2Kb haplotype, including C57BL/6. H-2Kb is involved in antigen presentation to T cells expressing CD3/TCR and CD8 proteins.

CD3/TCR, CD8

1. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25
2. Wieczorek M, et al. (2017) Front Immunol. 8:292
3. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9
4. Matsumura M, et al. (1992) Science. 257:927–34.10.1126/science.1323878
5. Bouvier M & Wiley DC. (1994) Science. 265:398–402.10.1126/science.8023162
6. Zacharias M & Springer S. (2004) Biophys J. 87:2203–14.10.1529/biophysj.104.044743
7. Cruz FM, et al (2017) Annu Rev Immunol. 35:149-176
8. Artyomov MN, et al (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
9. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856
10. Raulet DH. (1994) Adv Immunol. 55:381-421
11. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58